Affimed reported positive results in various cancer treatments trials, maintaining strong financial position.

From “GlobeNewswire”: 2024-09-05 06:30:00

Afimed N.V. reported promising results from AFM24 combination with atezolizumab for EGFRmut NSCLC patients: 1 CR, 3 PRs, and 8 SDs reported out of 17 response-evaluable patients, resulting in an ORR of 23.5% and DCR of 70.6%. Cash runway projected into H2 2025 with €34.4 million in cash reserves as of June 30, 2024.

Enrollment for r/r Hodgkin Lymphoma patients in cohorts 1 and 2 of Acimtamig (AFM13) and AlloNK (AB-101) completed, showing an impressive ORR of 83.3% and a CRR of 50%. AFM28 monotherapy study in r/r AML patients at dose level 6 (300 mg) resulted in 3 CR or CRi responses, prompting recruitment of additional patients.

Clinical data and financial results indicate Affimed’s commitment to advancing cancer treatments. LuminICE-203 study demonstrates efficacy in Hodgkin Lymphoma patients. AFM24 and AFM28 trials show encouraging results. Cash reserves of €34.4 million as of June 30, 2024, and projected to sustain operations into H2 2025.

Pipeline highlights from Affimed’s recent update show promising outcomes for cancer treatments, including EGFRmut NSCLC and r/r AML patients. Financial results indicate a solid cash position to support ongoing operations into the second half of 2025. Engagement in ongoing clinical development remains a key focus for the company.



Read more at “GlobeNewswire”:: Affimed Reports Second Quarter 2024 Financial Results &